Search results for "coagulation"

showing 10 items of 381 documents

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial

2014

Purpose To compare standard-of-care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branch retinal vein occlusion. Methods Prospective, randomized, multicentre clinical trial. Thirty patients with a best-corrected visual acuity (BCVA) between 20/320 and 20/40 were randomized 1:1:1 to receive grid laser or three monthly injections of 0.5 mg IVR or both followed by 3 months of observation. Results Mean change from baseline BCVA at month 6 was +2 letters [laser; 0.04 logMAR, 95% confidence interval (−0.17; 0.25)], +17 letters [IVR; 0.34 (0.19; 0.5)] and +6 letters [combination; 0.…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular Edemalaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRecurrencelawRanibizumabOphthalmologyRetinal Vein OcclusionHumansMedicineProspective Studies030212 general & internal medicineMacular edemaAgedAged 80 and overLaser Coagulationbusiness.industryRetinalGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence interval3. Good healthSurgeryClinical trialOphthalmologychemistryIntravitreal Injections030221 ophthalmology & optometryBranch retinal vein occlusionFemaleLasers SemiconductorRanibizumabmedicine.symptombusinessmedicine.drugActa Ophthalmologica
researchProduct

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

2007

Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous b…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentHemorrhagePostoperative HemorrhageGastroenterologyVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildProspective cohort studyAgedAged 80 and overHemostasisBleeding episodesFactor VIIIbiologybusiness.industryHematologyMiddle Agedmedicine.diseaseSurgeryClinical trialvon Willebrand DiseasesCoagulationChild PreschoolHemostasisConcomitantbiology.proteinFemaleSafetybusinessJournal of Thrombosis and Haemostasis
researchProduct

Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

2018

AbstractSince the impact of possible prothrombotic factors on blood coagulation resulting from exercise remains elusive, this study investigated the acute effects of middle-distance endurance running on blood coagulation parameters in middle-aged athletes. The study population consisted of 33 male endurance runners who were engaged in a 21.1 km run under competitive conditions. Blood samples were collected before the run, immediately after the run, and 3 hours after run completion. Samples were assessed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor antigen (VWF:Ag), endogenous thrombin potential (area…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyphysical activity030204 cardiovascular system & hematologyFibrinogenRunningblood coagulation03 medical and health sciences0302 clinical medicineVon Willebrand factorEndurance traininghemic and lymphatic diseasesInternal medicineABO blood group systemvon Willebrand FactormedicineHumansExerciseblood coagulation; hemostasis; physical activity; thrombin generation; Adult; Blood Coagulation; Exercise; Factor VIII; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Physical Endurance; Running; Thrombin; Thrombosis; von Willebrand Factor; AthletesProthrombin timeFactor VIIImedicine.diagnostic_testbiologyChemistryThrombinFibrinogenThrombosisHematologyMiddle Agedprothrombotic factors blood coagulation sportprothrombotic factorsEndocrinologyCoagulationAthletesthrombin generationHemostasishemostasisPhysical Endurancebiology.proteinPartial Thromboplastin TimeCardiology and Cardiovascular Medicinesportcirculatory and respiratory physiology030215 immunologyPartial thromboplastin timemedicine.drug
researchProduct

Unfractionated Heparin Versus Subcutaneous Nadroparin in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation: a Retrospective, Multi…

2021

Extracorporeal membrane oxygenation (ECMO) requires constant management of coagulation. Whereas unfractionated heparin remains the anticoagulant of choice, experienced centers report high bleeding rates. Biocompatibility of the extracorporeal circuit enables management of anticoagulation with subcutaneous low-molecular-weight heparins only. The aim of this study was to evaluate the safety and feasibility of anticoagulation with subcutaneous nadroparin compared with unfractionated heparin during respiratory ECMO in patients. We assessed for thrombotic complications and number of bleeding and life-threatening bleeding events. Additionally, we evaluated the change in resistance to flow in the …

AdultMalemedicine.drug_classmedicine.medical_treatmentBiomedical EngineeringBiophysicsBioengineering030204 cardiovascular system & hematologyExtracorporealBiomaterials03 medical and health sciencesExtracorporeal Membrane Oxygenation0302 clinical medicineExtracorporeal membrane oxygenationmedicineHumansanticoagulationOxygenatorRetrospective Studiesextracorporeal oxygenationHeparinbusiness.industryAnticoagulantAnticoagulantsThrombosisRetrospective cohort studyGeneral MedicineHeparinMiddle Agedunfractionated heparin030228 respiratory systemCoagulationAnesthesiaNadroparinnadroparinFemalebusinessmedicine.drugASAIO Journal
researchProduct

Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of …

2012

AdultMalemedicine.medical_specialtyAdolescentDeep veinRisk AssessmentGastroenterologyYoung AdultRisk FactorsInternal medicineOdds RatiomedicineFactor V LeidenHumansGenetic Predisposition to DiseaseIn patientChildBlood CoagulationAgedAged 80 and overVenous ThrombosisChi-Square DistributionProthrombin mutationbusiness.industryFactor VHematologyOdds ratioMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismPhenotypemedicine.anatomical_structureMeta-analysisMutationFemaleProthrombinPulmonary Embolismbusiness
researchProduct

Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys

2009

In a subgroup of hereditary angioedema (HAE) patients with normal C1-esterase inhibitor levels, HAE is caused by a Thr309Lys mutation in the coagulation factor XII (F12) gene. The aim of this study was to examine elements of the kallikrein-kinin system ('contact system') and the downstream-linked coagulation, complement and fibrinolytic systems in the plasma of six patients with HAE caused by the Thr309Lys mutation and healthy probands. Blood samples were taken from participants during the symptom-free interval between attacks. Samples were analyzed for activity and concentrations of components of the kallikrein-kinin system and linked enzyme systems. The mean FXII clotting activity was 90%…

AdultMalemedicine.medical_specialtyAdolescentMutation MissenseKininsCoagulation Factor XIIFactor XIIaGene mutationYoung AdultInternal medicinemedicineHumansPoint MutationHereditary Angioedema Type IIIComplement Pathway ClassicalAgedAged 80 and overFactor XIIAngioedemaChemistryFibrinolysisDextran SulfateAngioedemas HereditaryPrekallikreinPrekallikreinBlood ProteinsHematologyGeneral MedicineMiddle AgedSilicon Dioxidemedicine.diseaseEnzyme ActivationEndocrinologyAmino Acid SubstitutionChromogenic CompoundsCoagulationTissue Plasminogen ActivatorHereditary angioedemaImmunologyFemaleKallikreinsmedicine.symptomcirculatory and respiratory physiologyBlood Coagulation &amp; Fibrinolysis
researchProduct

Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis

2004

Background: Treatment of patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) is problematic if diagnostic imaging is not immediately available. Pretest clinical probability (PCP) and D-dimer assessment can be used to identify patients for whom empirical protective anticoagulation is indicated. To evaluate whether PCP and D-dimer assessment, together with the use of low-molecular-weight heparins (LMWHs), allow objective appraisal of DVT and PE to be deferred for up to 72 hours, patients with suspected DVT and PE were prospectively examined. Methods: Patients identified with a high PCP or a moderate PCP with positive D-dimer test results received a protective full-do…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classDeep veinLow molecular weight heparinFibrin Fibrinogen Degradation ProductsD-dimerInternal MedicinemedicineHumansRisk factoranticoagulationAgedAged 80 and overVenous ThrombosisPatientVascular diseasebusiness.industrylow molecular weight heparinAnticoagulantdeep vein thrombosisuspected PEHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureD dimerFemalePulmonary EmbolismbusinessAlgorithmsFollow-Up StudiesArchives of Internal Medicine
researchProduct

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct

Subfascial Endoscopic Perforator Surgery With Tumescent Local Anesthesia

2002

background. Subfascial endoscopic perforator surgery (SEPS) has become an established procedure. objective. To evaluate SEPS with tumescent local anesthesia (TLA) using an single-port device originally designed for that purpose. methods. Patients selected for SEPS received subcutaneous infiltration of TLA into the medial aspect of the calf 20 minutes before surgery. Bipolar coagulation and dissection were used to treat incompetent perforators. results. Fifty-one patients with 67 legs of CEAP stages C3–C6 underwent SEPS with TLA. In 40 patients or 53 legs (79.1%) TLA alone allowed successful completion of the SEPS procedure. Five patients with 7 legs (10.4%) required additional intravenous a…

AdultMalemedicine.medical_specialtyConscious SedationSuccessful completionDermatologyVaricose UlcerPain controlmedicineHumansLocal anesthesiaIn patientAgedEndoscopesLegVascular diseasebusiness.industryEquipment DesignGeneral MedicineMiddle AgedIncompetent perforatorsmedicine.diseaseSurgerybody regionsTreatment OutcomeVenous InsufficiencyAnesthesiaFemaleSurgeryVenous diseasebusinessVascular Surgical ProceduresBipolar coagulationAnesthesia LocalDermatologic Surgery
researchProduct

Reduced recanalization rates of the great saphenous vein after endovenous laser treatment with increased energy dosing: Definition of a threshold for…

2006

Background Recent reports indicated a correlation between the amount of energy released during endovenous laser treatment (ELT) of the great saphenous vein (GSV) and the success and durability of the procedure. Our objective was to analyze the influence of increased energy dosing on immediate occlusion and recanalization rates after ELT of the GSV. Methods GSVs were treated with either 15 or 30 W of laser power by using a 940-nm diode laser with continuous fiber pullback and tumescent local anesthesia. Patients were followed up prospectively with duplex ultrasonography at day 1 and at 1, 3, 6, and 12 months. Results A total of 114 GSVs were treated with 15 W, and 149 GSVs were treated with …

AdultMalemedicine.medical_specialtyDuplex ultrasonographyTime FactorsAdolescentmedicine.medical_treatmentAngioscopyOcclusionmedicineHumansSaphenous VeinLocal anesthesiaProspective StudiesDosingVeinAgedAged 80 and overUltrasonography Doppler DuplexLaser Coagulationmedicine.diagnostic_testbusiness.industryGreat saphenous veinEndovenous laser treatmentMiddle AgedAngioscopySurgeryTreatment Outcomemedicine.anatomical_structureVenous InsufficiencyChronic DiseaseFemaleSurgeryCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Vascular Surgery
researchProduct